NWBO CTIX SNTA SBFM THLD PCYC IMUC CUR ISCO
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
FDA News
Dec 30 (Reuters) - The number of new drugs approved in the United States fell in 2013 compared with the previous year as fewer applications were filed, though several products for hard-to-treat diseases were approved in record time.
The U.S. Food and Drug Administration approved 27 new drugs in 2013, down from a banner year in 2012 which saw 39 drugs approved, the greatest number since 1997 according to FDA data.
The regulatory agency attributed the drop in approvals in 2013 to fewer applications. As of Dec. 11, 32 applications had been filed, compared with 41 for 2012, the FDA said. Over the past five years, the average number of new drug filings per year was 35.
In July 2012, as part of the Food and Drug Administration Safety and Innovation Act, the FDA introduced the "breakthrough therapy" designation to help speed drugs to market that treat serious or life-threatening conditions and where preliminary evidence suggests the drug may work better than existing treatments.
The FDA's Center for Drug Evaluation and Research (CDER) has received 120 requests for breakthrough therapy designation, of which it has granted 36 requests and denied 58. The remainder were pending or withdrawn at the end of the year.
The agency has approved three products so far under the breakthrough therapy program: Roche Holding AG's leukemia drug Gazyva; Johnson & Johnson's drug Imbruvica for mantle cell lymphoma, a rare form of non-Hodgkin lymphoma; and Gilead Sciences Inc's hepatitis C drug Sovaldi.
The number of drugs approved by CDER in 2013, though down from 2012, is close to the historical average over the past five years of 28, according to a recent FDA industry presentation.
The average internal rate of return from pharmaceutical research and development fell to around 4.8 percent in 2013 from 7.2 percent last year and 10.5 percent in 2010, according to a study released earlier this month by Deloitte and Thomson Reuters.
Over the same four-year period, the average cost of developing new medicines rose 18 percent to $1.3 billion, the report found. Yet the average peak sales forecast for each new drug dropped 43 percent to $466 million in 2013 from $816 million in 2010, the report found.
Nonetheless, some analysts remain optimistic that output will increase along with advances in science.
"We are confident that changes to R&D strategies ... will drive a significant improvement in output over the next decade," a Deutsche Bank report said this month.
Reloaded for the march to ASCO and not looking behind me. It looks like the breakout is Here Now
BIG Brother is on your phone
New York Times
Judge Upholds N.S.A.’s Bulk Collection of Data on Calls
By ADAM LIPTAK and MICHAEL S. SCHMIDT
Published: December 27, 2013
WASHINGTON — A federal judge on Friday ruled that a National Security Agency program that collects enormous troves of phone records is legal, making the latest contribution to an extraordinary debate among courts and a presidential review group about how to balance security and privacy in the era of big data.
Related in Opinion
In just 11 days, the two judges and the presidential panel reached the opposite of consensus on every significant question before them, including the intelligence value of the program, the privacy interests at stake and how the Constitution figures in the analysis.
The latest decision, from Judge William H. Pauley III in New York, could not have been more different from one issued on Dec. 16 by Judge Richard J. Leon in Washington, who ruled that the program was “almost Orwellian” and probably unconstitutional.
The decision on Friday “is the exact opposite of Judge Leon’s in every way, substantively and rhetorically,” said Orin S. Kerr, a law professor at George Washington University. “It’s matter and antimatter.”
The case in New York was brought by the American Civil Liberties Union, which said it would appeal.
“We are extremely disappointed with this decision, which misinterprets the relevant statutes, understates the privacy implications of the government’s surveillance and misapplies a narrow and outdated precedent to read away core constitutional protections,” said Jameel Jaffer, a lawyer with the group.
A spokesman for the Justice Department said, “We are pleased the court found the N.S.A.’s bulk telephony metadata collection program to be lawful.”
The next stops for the parallel cases are the appeals courts in New York and Washington. Should the split endure, the Supreme Court is likely to step in.
In the meantime, the decisions, along with recommendations issued on Dec. 18 by the presidential review group, illustrate the absence of agreement about the effectiveness and legality of the program, which, Judge Pauley said, “vacuums up information about virtually every telephone call to, from or within the United States.” That information is “metadata” — the phone numbers involved, when calls were made and how long they lasted.
The two judges had starkly differing understandings on how valuable that program is.
Judge Pauley, whose courtroom is just blocks from where the World Trade Center towers stood, endorsed arguments made in recent months by senior government officials — including the former F.B.I. director Robert S. Mueller III — that the program might have caught the Sept. 11, 2001, hijackers had it been in place before the attacks.
Judge Pauley began his opinion with an anecdote. In the months before Sept. 11, he said, the N.S.A. intercepted seven calls made to a Qaeda safe house in Yemen from the United States. They were from Khalid al-Mihdhar, who was living in San Diego and would become one of the hijackers.
But the security agency “could not capture al-Mihdhar’s telephone number,” the judge wrote, and “N.S.A. analysts concluded mistakenly that al-Mihdhar was overseas and not in the United States.”
“Telephony metadata would have furnished the missing information and might have permitted the N.S.A. to notify the Federal Bureau of Investigation of the fact that al-Mihdhar was calling the Yemeni safe house from inside the United States,” Judge Pauley wrote.
Judge Leon, in Washington, took the opposite view, saying the government had failed to make the case that the program is needed to protect the nation. “The government does not cite a single instance in which analysis of the N.S.A.’s bulk metadata collection actually stopped an imminent attack, or otherwise aided the government in achieving any objective that was time-sensitive in nature,” he wrote.
The presidential review group took a middle ground, though it seemed to lean toward Judge Leon’s position. It said the security agency “believes that on at least a few occasions” the program “has contributed to its efforts to prevent possible terrorist attacks, either in the United States or somewhere else in the world.” But it added that its own review suggested that the program “was not essential to preventing attacks,” and that less intrusive measures would work.
The group recommended that bulk storage of telephone records by the government be halted in favor of “a system in which such metadata is held instead either by private providers or by a private third party.” Access to the data, it said, should require a court order.
The two judges did not limit their disagreements to how well the program worked. They also drew different conclusions about its constitutionality.
In regard to that it appears there is not much of value going on there since I took a break. Back in the teens we are....Is anyone forecasting the date of the IND yet? wake me from my nap when that happenss. ZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZ
Shares under $2.00
Will be considered cheaper than dirt by the middle of next baseball season. Some think that is far off. Those without any
patience should hire full service brokers and play golf.
Those with patience will have money for NEW Pings and round at
St Andrews and treating the foursome at some fine Scottish establishment later that evening. CTIX will in my view be the
most talked about company at ASCO 2014. The catalyst news cycle
rules biotech stock performance and that continues. Stay tuned
I remain
T H E Biomanbaba
Thank you. I will stop by on major events to comment. Offline issues still taking much of my time. For those who follow CUR remains my overweight position. I continue to believe this is a fantastic investment.
It appears Aprils latest blog gives us all reason to hope for the end of ALS sooner rather than later. Great results and more progress by April may make the pages of important publications in the near future. The media buzz from that will likely bring a great deal of attention to this board. I would advise all commenting here to think about what you say. Write like you might be quoted in the NY Times or WSJ. It may happen sooner than some think.
Status update....My commentary may be minimal during the balance of 2013. Interests outside of IHUB are taking up substantial amounts of my time.The lack of remarks should NOT be considered any change of opinion by me.
This one referred to in yours has more science based DD
http://www.pvct.com/news/OncologyNews-Nov-2013.pdf
It should be studied. Bring whatever you find to the board.
Kelt If I knew that I would not keep it a secret. Anyones WAG is as good as mine right now. I would trust SEEL to update us if she changes her opinion about December.
that one is a long term play. I think their product will be successful but the share price price may not reflect it until after Kevetrin comes in or CUR moves etc. I dont have room for it in my current strategy
An excellent article Bucky thanks for bringing it to the board. All should read.
I dont know the answer to that one. It is usually reported
outstanding results as you forecasted
Hello Kelt
Most here are locked and loaded and have been for some time. They are watch Aprils blog seeing that she is feeling much better after
getting her stem cells. We are approaching the time when the secret can NO LONGER BE KEPT. ALS patients are about to get MUCH BETTER
Rock and Roll Starbux
Those who ignored your call are now eating CROW huh?
We told them to buy now or pay up later
It is now time for the procrastinators to PAY UP
What is your forecast for this run underway?
ECTE has momentum
Volume at record pace first hour
Blast off underway today
Procrastinators your TIME IS UP
hot diggetty damn
Neuralstem it is time to rock and roll
sounds like that deserves a hot diggetty damn
This EOD profit taking by some daytraders SHOULD BE BOUGHT by long term investors......dont miss the bargains because they wont last
Yeah LOL I am glad I pounded the table with you BEFORE it came out but that was lucky for both of us
Yeah and conservative indeed. The fact is a PR about Breakthrough designation by the FDA will launch this rocket to $25 and it is entirely possible. $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
ba ba ba boooooooooooooooooooooooom
and hot diggetty damn
We know that is a conservative forecast but still almost a double from here.If their call happens MOMENTUM will take it much further than they are willing to speculate about
Aegis Capital analyst remarks posted today
Neuralstem, Inc.
Rating: Buy
Upcoming Catalysts: Raising Price Target
Investment Highlights:
¦ Significant Milestones Ahead - Raising Price Target. In our view,
Neuralstem is entering a critical period in its history, with potentially
imminent initiation of dosing in a proof-of-concept Phase 1 / 2 trial of its
lead stem cell-based therapeutic product candidate, NSI-566, in spinal cord
injury (SCI). We also note that the company is slated to report data from
the Phase 1b trial of its small molecule agent, NSI-189, within the coming
weeks and should report data with NSI-566 in a Phase 2 trial enrolling
patients with amyotrophic lateral sclerosis (ALS) by mid-2014. If this ALS
data shows activity of the drug in maintaining and / or improving forced
vital capacity, a measure of breathing capability in these patients, we believe
that NSI-566 could qualify for accelerated approval. In anticipation of these
clinical catalysts, we reiterate our Buy rating and raise our 12-month price
target from $4.00 to $4.50 per share on CUR.
¦ Solid Financial Position. Neuralstem ended the third quarter of 2013 with
$16.4mm in cash and equivalents. We note that the company's operational
burn rate through the next nine months is likely to be relatively low, since
most of its clinical development initiatives are likely to receive substantial
non-dilutive funding from academic institutions. Accordingly, we believe that
Neuralstem should be able to fund operations with existing capital for the
next several quarters. Investors should note that the firm has 18.6mm in-themoney
warrants that could accrue over $30mm to the company if exercised.
We would anticipate that, if warrant exercises were to continue as envisaged,
Neuralstem should comfortably be able to fund operations into late 2015.
¦ Additional Clinical Initiatives Under Way Ex-U.S. We expect Neuralstem
to begin testing of NSI-566 in ALS patients in a Phase 1/2 study in Mexico
early in 2014, after filing its IND by the end of the year. Also, the firm is slated
to start a Phase 1/2 study of NSI-566 in ischemic stroke patients in China.
This study is being conducted at the Bayi Brain Hospital and is designed to
enroll up to 18 patients in a dose-escalation study. There are about 1.75mm
stroke patients in China. If successful, this Phase 1/2 trial could pave the way
for a larger, 100-patient Phase 2 study. The firm also plans to file another IND
to begin a Phase 1 acute SCI trial in South Korea before the end of 2013.
That is a substantial and useful post Bucky
For those who dont know; APRIL is our star blogger/ALS patient.
All who are new or on board lately should review your post.
I believe her remarks are significant.
Let me be clear
I have done NO analysis of your stock or any in that sector. I avoid all stocks in that sector for reasons UNRELATED to fundamental or technical analysis. It is about politics. Their is political CONSENSUS about the need for faster drug approvals by FDA and the
"Breakthrough Act" was passed with bipartisan support. There is an ongoing war between the parties over ATF issues. Further let me state that my opinion on the sector is NOT ADVICE to anyone.
VAP analysis for those who understand it
targeting the move that breaks $3
we have to clear 2.84 on volume greater than 4.5 million
this move will break the backs of all selling interest
and could produce MOMENTUM taking us past $5
Thursdays run fell short of setting momentum in motion
however many more eyes are now focused on CUR due to the
Forbes article. Fridays profit taking did nothing to damage
the upward bias here. 2 million shares are now in
stronger hands playing the next element of the Catalyst News
Cycle. News waiting in the wings here mean that CUR is
like a wound spring. The next meaningful news takes us
PARABOLIC.
I remain
T H E biomanbaba
Holder LIED to cover his behind
n all, ATF officials permitted more than 1,700 semi-automatic weapons to flow through the hands of straw buyers for the Mexican cartels, with many crossing the border.
Senior ATF officials hoped to trace the guns to crimes, then make a bigger case against the Mexican drug lords. The strategy, however, backfired when hundreds of the weapons began showing up at crime scenes on both sides of the border, including at the December 2010 murder of U.S. Border Patrol Agent Brian Terry.
The Justice Department initially denied guns knowingly had been allowed to flow across the border, then months later reversed course and admitted the tactic had been used for more than a year. The change in story led to allegations of a cover-up.
The revelations exploded into public in spring 2011, catapulting Mr. Dodson and other ATF field agents who had objected into dual investigations by Congress and the Justice Department inspector general.
President Obama and Attorney General Eric H. Holder Jr. both claimed they knew nothing about the strategy until the controversy erupted, but the president has invoked executive privilege to block Congress from seeing certain documents, thus thwarting the completion of that probe. A court recently ruled in favor of Congress in the ongoing legal dispute.
Both the congressional and inspector general investigations concluded that the gun-walking tactics were poorly conceived and put lives in jeopardy. The fallout forced the ouster of numerous top officials, including the U.S. attorney in Phoenix, Dennis Burke, and the acting director of the ATF, Kenneth Melson.
Read more: http://www.washingtontimes.com/news/2013/oct/6/atf-tries-block-whistleblowing-agents-fast-and-fur/#ixzz2lPJMgkGO
Follow us: @washtimes on Twitter
ATF is in Turmoil
Eric Holder is incompetent and should be impeached
http://www.washingtontimes.com/news/2013/oct/6/atf-tries-block-whistleblowing-agents-fast-and-fur/?page=all
Neuralstem Cell Therapy for ALS
Product status:
U.S.: FDA-approved NSI-566 Phase II trial commenced in September 2013; Phase I safety trial ended in February 2013
Mexico City: NSI-566 Phase I / II trial expected to commence in 2014
Mechanism of Action: Rebuilding neural circuitry
Route of Administration: Direct injections into the spinal cord
Neuralstem is seeking to treat the symptoms of ALS via transplantation of its NSI-566 human spinal cord stem cells (HSSCs) directly into the gray matter of the patient’s spinal cord. In ALS, motor neurons die, leading to paralysis. In preclinical animal work, Neuralstem cells both made synaptic contact with the host motor neurons and expressed neurotrophic growth factors, which are protective of cells. View published papers here: 1, 2, 3.
Neuralstem initiated the first FDA-approved stem cell trial for ALS in January 2010, at Emory University. This Phase I safety trial, to evaluate the safety of the NSI-566 cells and surgical technique, was designed to enroll up to 18 patients. The Principal Investigator is Eva Feldman, MD, PhD, Director of the A. Alfred Taubman Medical Research Institute, Director of Research of the ALS Clinic at the University of Michigan Health System, and President of the American Neurological Association. The Site Investigator is Jonathan Glass, MD, Professor of Neurology, Emory School of Medicine and Director of the Emory ALS Center. The trial was awarded an Orphan Drug Designation by the FDA in February 2011.
In humans, Neuralstem expects that the transplanted cells will:
GRAFT permanently into the region where they were transplanted
REBUILD circuitry with the patient motor neurons
PROTECT patient neurons from further ravages of the disease
In a review of the safety data from the initial nine patients, Neuralstem cells were deemed to be safe, with no adverse reactions reported believed to be related to cells or surgical technique.
Neuralstem ALS Trial
Neuralstem received FDA approval to commence the NSI-566/ALS Phase II trial in April 2013, following conclusion of its Phase I FDA-approved trial to test the safety of its cells and transplantation surgery in patients with ALS in February 2013. The National Institutes of Health and ALSA have committed to generous grants in funding for this phase of the study.
The NSI-566/ALS Phase II dose escalation and safety trial commenced in September 2013, and expanded to two centers: Emory University Hospital in Atlanta, Georgia, site of Phase I, and ALS Clinic at the University of Michigan Health System, in Ann Arbor, Michigan, subject to approval by the Institutional Review Board at each institution. The trial is designed to treat up to 15 patients, in five different dosing cohorts, advancing up to a maximum of 40 injections, and 400,000 cells per injection based on safety. (Phase I maximum was 15 injections of 100,000 cells each.) All of the patients will be ambulatory and reside within close geographic proximity to the research center where they will participate. The first 12 patients will receive injections in the cervical region of the spinal cord only, where the stem cells could help preserve breathing function. The final three patients will receive both cervical and lumbar injections.
The Phase I safety trial enrolled 18 patients. The trial began with 12 late- to mid-stage patients who received a series of injections in the L2-L4 lumbar region. The first six patients were all non-ambulatory with permanent paralysis. Of these, the first three patients (Cohort A1) were treated with five unilateral cell injections, while the next three patients (Cohort A2) received ten bilateral injections in the same region. The trial then progressed to patients who were ambulatory. The first three of these (Cohort B) received five unilateral injections. The next three patients (Cohort C) received ten bilateral injections in the same lumbar region.
Neuralstem received approval from the FDA to move into the cervical (upper back) stage of the trial in the fall of 2011. The first of six patients in the cervical cohorts to receive stem cells was treated on November 18, 2011, which marked the first FDA-approved intraspinal surgical transplantation of stem cells into the cervical region. The trial then advanced to the final cervical cohort of three patients. The FDA approved the return of three patients from earlier cohorts to receive cervical transplants, making them the first to receive stem cell transplantation in both the lower and upper parts of their spinal cord. The first of these was treated in June 2012, and received five stem cell injections into the cervical region of the back, for a total of 15 injections, including the ten lower-back injections previously received. The last patient in the Phase I trial was treated in August 2012. The trial was designed as a safety trial to treat 18 patients, and conclude six months after the final surgery.
In Mexico City, Neuralstem is expected to commence an ALS Phase I / II trial in 2014.
VIDEO FOX Medical Team In-depth Feature on ALS Patient Ted Harada and his second, the trial’s final, surgery of Neuralstem's ground-breaking Phase I stem cell trial (8/27/12). View Here
Patient Resources:
For more information on the trial:
University of Michigan Health System, Ann Arbor http://www.umclinicalstudies.org/HUM00072488, http://www.pnrd.umich.edu
Emory Healthcare, Atlanta (404) 778-7777 http://www.neurology.emory.edu/ALS/Support%20Our%20Center/active_trials/stem_cell_trial.html
ClinicalTrials.gov
http://clinicaltrials.gov/ct2/show/NCT01348451?term=neuralstem&rank=2
Interim Results of Phase I ALS trial:
Abstract, NIH/National Center for Biotechnology Information (NCBI): "Lumbar Intraspinal Injection of Neural Stem Cells in Patients with ALS: Results of a Phase I Trial in 12 Patients." (March 2012) Here
Presentation Poster, presented at American Neurological Association’s annual meeting (September 2011). Here
Safety Study to use Electrical Impedance Myography (EIM) as a measurement tool in Neuralstem's ALS trials (April 2011). Here
"Approaching Hope," by Nancy Ross-Flanigan, Michigan Alumnus magazine, Spring 2011. Here
For more information on ALS:
The ALS Association www.alsa.org
- See more at: http://neuralstem.com/cell-therapy-for-als#sthash.t7tOhrZA.dpuf
Neuralstem Cell Therapy for ALS
Product status:
U.S.: FDA-approved NSI-566 Phase II trial commenced in September 2013; Phase I safety trial ended in February 2013
Mexico City: NSI-566 Phase I / II trial expected to commence in 2014
Mechanism of Action: Rebuilding neural circuitry
Route of Administration: Direct injections into the spinal cord
Neuralstem is seeking to treat the symptoms of ALS via transplantation of its NSI-566 human spinal cord stem cells (HSSCs) directly into the gray matter of the patient’s spinal cord. In ALS, motor neurons die, leading to paralysis. In preclinical animal work, Neuralstem cells both made synaptic contact with the host motor neurons and expressed neurotrophic growth factors, which are protective of cells. View published papers here: 1, 2, 3.
Neuralstem initiated the first FDA-approved stem cell trial for ALS in January 2010, at Emory University. This Phase I safety trial, to evaluate the safety of the NSI-566 cells and surgical technique, was designed to enroll up to 18 patients. The Principal Investigator is Eva Feldman, MD, PhD, Director of the A. Alfred Taubman Medical Research Institute, Director of Research of the ALS Clinic at the University of Michigan Health System, and President of the American Neurological Association. The Site Investigator is Jonathan Glass, MD, Professor of Neurology, Emory School of Medicine and Director of the Emory ALS Center. The trial was awarded an Orphan Drug Designation by the FDA in February 2011.
In humans, Neuralstem expects that the transplanted cells will:
GRAFT permanently into the region where they were transplanted
REBUILD circuitry with the patient motor neurons
PROTECT patient neurons from further ravages of the disease
In a review of the safety data from the initial nine patients, Neuralstem cells were deemed to be safe, with no adverse reactions reported believed to be related to cells or surgical technique.
Neuralstem ALS Trial
Neuralstem received FDA approval to commence the NSI-566/ALS Phase II trial in April 2013, following conclusion of its Phase I FDA-approved trial to test the safety of its cells and transplantation surgery in patients with ALS in February 2013. The National Institutes of Health and ALSA have committed to generous grants in funding for this phase of the study.
The NSI-566/ALS Phase II dose escalation and safety trial commenced in September 2013, and expanded to two centers: Emory University Hospital in Atlanta, Georgia, site of Phase I, and ALS Clinic at the University of Michigan Health System, in Ann Arbor, Michigan, subject to approval by the Institutional Review Board at each institution. The trial is designed to treat up to 15 patients, in five different dosing cohorts, advancing up to a maximum of 40 injections, and 400,000 cells per injection based on safety. (Phase I maximum was 15 injections of 100,000 cells each.) All of the patients will be ambulatory and reside within close geographic proximity to the research center where they will participate. The first 12 patients will receive injections in the cervical region of the spinal cord only, where the stem cells could help preserve breathing function. The final three patients will receive both cervical and lumbar injections.
The Phase I safety trial enrolled 18 patients. The trial began with 12 late- to mid-stage patients who received a series of injections in the L2-L4 lumbar region. The first six patients were all non-ambulatory with permanent paralysis. Of these, the first three patients (Cohort A1) were treated with five unilateral cell injections, while the next three patients (Cohort A2) received ten bilateral injections in the same region. The trial then progressed to patients who were ambulatory. The first three of these (Cohort B) received five unilateral injections. The next three patients (Cohort C) received ten bilateral injections in the same lumbar region.
Neuralstem received approval from the FDA to move into the cervical (upper back) stage of the trial in the fall of 2011. The first of six patients in the cervical cohorts to receive stem cells was treated on November 18, 2011, which marked the first FDA-approved intraspinal surgical transplantation of stem cells into the cervical region. The trial then advanced to the final cervical cohort of three patients. The FDA approved the return of three patients from earlier cohorts to receive cervical transplants, making them the first to receive stem cell transplantation in both the lower and upper parts of their spinal cord. The first of these was treated in June 2012, and received five stem cell injections into the cervical region of the back, for a total of 15 injections, including the ten lower-back injections previously received. The last patient in the Phase I trial was treated in August 2012. The trial was designed as a safety trial to treat 18 patients, and conclude six months after the final surgery.
In Mexico City, Neuralstem is expected to commence an ALS Phase I / II trial in 2014.
VIDEO FOX Medical Team In-depth Feature on ALS Patient Ted Harada and his second, the trial’s final, surgery of Neuralstem's ground-breaking Phase I stem cell trial (8/27/12). View Here
Patient Resources:
For more information on the trial:
University of Michigan Health System, Ann Arbor http://www.umclinicalstudies.org/HUM00072488, http://www.pnrd.umich.edu
Emory Healthcare, Atlanta (404) 778-7777 http://www.neurology.emory.edu/ALS/Support%20Our%20Center/active_trials/stem_cell_trial.html
ClinicalTrials.gov
http://clinicaltrials.gov/ct2/show/NCT01348451?term=neuralstem&rank=2
Interim Results of Phase I ALS trial:
Abstract, NIH/National Center for Biotechnology Information (NCBI): "Lumbar Intraspinal Injection of Neural Stem Cells in Patients with ALS: Results of a Phase I Trial in 12 Patients." (March 2012) Here
Presentation Poster, presented at American Neurological Association’s annual meeting (September 2011). Here
Safety Study to use Electrical Impedance Myography (EIM) as a measurement tool in Neuralstem's ALS trials (April 2011). Here
"Approaching Hope," by Nancy Ross-Flanigan, Michigan Alumnus magazine, Spring 2011. Here
For more information on ALS:
The ALS Association www.alsa.org
- See more at: http://neuralstem.com/cell-therapy-for-als#sthash.t7tOhrZA.dpuf
MEDIA attention will be
The hammer that drives the last nail in the naysayers coffin. The bears are shot and wounded and will soon be dead here.
On 189 could be any day on 566 that is a wag
This one will NOT CRAWL it is news driven. When the NEWS comes it will rocket...maybe to $5 in one day
Your keen advice should be paid attention to. Unfortunately as I have learned over the years some listen and make money and others never get it. You help those WHO CAN BE HELPED and pray for the rest. ISCO is on a clear path to an Earth Moving IND. The end of Parkinson's Disease lies before us as we watch history unfold.
We might have to watch the snow fall and melt first...but it damn sure will and when it does ISCO will blast off bigtime. I am enjoying adding cheap here.......tip toeing through the tulips and watching the madness evolve around me. Being early requires patience